Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Gain-of-function mutant p53: history and speculation.

Bargonetti J, Prives C.

J Mol Cell Biol. 2019 Jul 8. pii: mjz067. doi: 10.1093/jmcb/mjz067. [Epub ahead of print] No abstract available.

PMID:
31283823
2.

p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.

Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP 4th, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, de Stanchina E, Zender L, Tong DR, D'Alessandro A, Lowe SW, Prives C.

Cell. 2019 Jan 24;176(3):564-580.e19. doi: 10.1016/j.cell.2018.11.011. Epub 2018 Dec 20.

3.

Unfolding the roles of resveratrol in p53 regulation.

Muniz de Queiroz R, Prives C.

Oncotarget. 2018 Oct 2;9(77):34455-34456. doi: 10.18632/oncotarget.26185. eCollection 2018 Oct 2. No abstract available.

4.

Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.

Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, Manley JL, Mikoshiba K, Onuchic JN, Pass HI, Pinton P, Prives C, Rothman N, Sebti SM, Turkson J, Wu X, Yang H, Yu H, Melino G.

Cell Death Differ. 2018 Nov;25(11):1885-1904. doi: 10.1038/s41418-018-0213-5. Epub 2018 Oct 15.

PMID:
30323273
5.

The C9ORF72 Gene, Implicated in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Encodes a Protein That Functions in Control of Endothelin and Glutamate Signaling.

Fomin V, Richard P, Hoque M, Li C, Gu Z, Fissore-O'Leary M, Tian B, Prives C, Manley JL.

Mol Cell Biol. 2018 Oct 29;38(22). pii: e00155-18. doi: 10.1128/MCB.00155-18. Print 2018 Nov 15.

6.

Correction: Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus.

Karni-Schmidt O, Friedler A, Zupnick A, McKinney K, Mattia M, Beckerman R, Bouvet P, Sheetz M, Fersht A, Prives C.

Oncogene. 2018 Aug;37(35):4901-4902. doi: 10.1038/s41388-018-0321-1.

PMID:
30068941
7.

STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis.

Rokudai S, Li Y, Otaka Y, Fujieda M, Owens DM, Christiano AM, Nishiyama M, Prives C.

Proc Natl Acad Sci U S A. 2018 May 22;115(21):E4806-E4814. doi: 10.1073/pnas.1718546115. Epub 2018 May 7.

8.

Accurate and sensitive quantification of protein-DNA binding affinity.

Rastogi C, Rube HT, Kribelbauer JF, Crocker J, Loker RE, Martini GD, Laptenko O, Freed-Pastor WA, Prives C, Stern DL, Mann RS, Bussemaker HJ.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3692-E3701. doi: 10.1073/pnas.1714376115. Epub 2018 Apr 2.

9.

Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers.

Katz C, Low-Calle AM, Choe JH, Laptenko O, Tong D, Joseph-Chowdhury JN, Garofalo F, Zhu Y, Friedler A, Prives C.

Genes Dev. 2018 Mar 1;32(5-6):430-447. doi: 10.1101/gad.304071.117. Epub 2018 Mar 16.

10.

Relevance of the p53-MDM2 axis to aging.

Wu D, Prives C.

Cell Death Differ. 2018 Jan;25(1):169-179. doi: 10.1038/cdd.2017.187. Epub 2017 Dec 1. Review.

11.

Dysfunction of the MDM2/p53 axis is linked to premature aging.

Lessel D, Wu D, Trujillo C, Ramezani T, Lessel I, Alwasiyah MK, Saha B, Hisama FM, Rading K, Goebel I, Schütz P, Speit G, Högel J, Thiele H, Nürnberg G, Nürnberg P, Hammerschmidt M, Zhu Y, Tong DR, Katz C, Martin GM, Oshima J, Prives C, Kubisch C.

J Clin Invest. 2017 Oct 2;127(10):3598-3608. doi: 10.1172/JCI92171. Epub 2017 Aug 28.

12.

Erratum: Retraction for Gonzalez et al., "p73α Regulation by Chk1 in Response to DNA Damage".

Gonzalez S, Prives C, Cordon-Cardo C.

Mol Cell Biol. 2017 Aug 28;37(18). pii: e00365-17. doi: 10.1128/MCB.00365-17. eCollection 2017 Sep 15.

13.

p53: master of life, death, and the epigenome.

Laptenko O, Prives C.

Genes Dev. 2017 May 15;31(10):955-956. doi: 10.1101/gad.302364.117. Review.

14.

Quantitative Analysis of the DNA Methylation Sensitivity of Transcription Factor Complexes.

Kribelbauer JF, Laptenko O, Chen S, Martini GD, Freed-Pastor WA, Prives C, Mann RS, Bussemaker HJ.

Cell Rep. 2017 Jun 13;19(11):2383-2395. doi: 10.1016/j.celrep.2017.05.069.

15.

STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Otaka Y, Rokudai S, Kaira K, Fujieda M, Horikoshi I, Iwakawa-Kawabata R, Yoshiyama S, Yokobori T, Ohtaki Y, Shimizu K, Oyama T, Tamura J, Prives C, Nishiyama M.

Clin Cancer Res. 2017 Jul 1;23(13):3442-3452. doi: 10.1158/1078-0432.CCR-16-1815. Epub 2017 Jan 13.

16.

Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.

Pfister NT, Prives C.

Cold Spring Harb Perspect Med. 2017 Feb 1;7(2). pii: a026054. doi: 10.1101/cshperspect.a026054. Review.

17.

Targeting mutant p53 through the mevalonate pathway.

Freed-Pastor W, Prives C.

Nat Cell Biol. 2016 Oct 27;18(11):1122-1124. doi: 10.1038/ncb3435. Review.

PMID:
27784901
18.

Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells.

Yoh KE, Regunath K, Guzman A, Lee SM, Pfister NT, Akanni O, Kaufman LJ, Prives C, Prywes R.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6107-E6116. Epub 2016 Sep 28.

19.

The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein.

Laptenko O, Tong DR, Manfredi J, Prives C.

Trends Biochem Sci. 2016 Dec;41(12):1022-1034. doi: 10.1016/j.tibs.2016.08.011. Epub 2016 Sep 23. Review.

20.

Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.

Beckerman R, Yoh K, Mattia-Sansobrino M, Zupnick A, Laptenko O, Karni-Schmidt O, Ahn J, Byeon IJ, Keezer S, Prives C.

Cell Cycle. 2016 Jun 2;15(11):1425-38. doi: 10.1080/15384101.2016.1170270. Epub 2016 May 21.

21.

Chromatin dysregulation by mutant p53.

Pfister NT, Prives C.

Oncotarget. 2016 May 24;7(21):29875-6. doi: 10.18632/oncotarget.7922. No abstract available.

22.

The Roles of MDM2 and MDMX in Cancer.

Karni-Schmidt O, Lokshin M, Prives C.

Annu Rev Pathol. 2016 May 23;11:617-44. doi: 10.1146/annurev-pathol-012414-040349. Epub 2016 Mar 17. Review.

23.

Cancer: Mutant p53 and chromatin regulation.

Prives C, Lowe SW.

Nature. 2015 Sep 10;525(7568):199-200. doi: 10.1038/nature15212. Epub 2015 Sep 2. No abstract available.

24.

Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.

Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C.

Genes Dev. 2015 Jun 15;29(12):1298-315. doi: 10.1101/gad.263202.115. Epub 2015 Jun 16.

25.

The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain.

Laptenko O, Shiff I, Freed-Pastor W, Zupnick A, Mattia M, Freulich E, Shamir I, Kadouri N, Kahan T, Manfredi J, Simon I, Prives C.

Mol Cell. 2015 Mar 19;57(6):1034-1046. doi: 10.1016/j.molcel.2015.02.015.

26.

p53, DNA damage, and NAD+ homeostasis.

Pfister NT, Yoh KE, Prives C.

Cell Cycle. 2014;13(11):1661-2. doi: 10.4161/cc.29151. Epub 2014 May 8. No abstract available.

27.

Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.

Weissmueller S, Manchado E, Saborowski M, Morris JP 4th, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, Grimmond SM, Pilarsky C, Prives C, Biankin AV, Lowe SW.

Cell. 2014 Apr 10;157(2):382-394. doi: 10.1016/j.cell.2014.01.066.

28.

Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry.

Zhu Y, Regunath K, Jacq X, Prives C.

Genes Dev. 2013 Aug 15;27(16):1739-51. doi: 10.1101/gad.212258.112. Epub 2013 Aug 9.

29.

Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network.

Daftuar L, Zhu Y, Jacq X, Prives C.

PLoS One. 2013 Jul 16;8(7):e68667. doi: 10.1371/journal.pone.0068667. Print 2013.

30.

UV-triggered p21 degradation facilitates damaged-DNA replication and preserves genomic stability.

Mansilla SF, Soria G, Vallerga MB, Habif M, Martínez-López W, Prives C, Gottifredi V.

Nucleic Acids Res. 2013 Aug;41(14):6942-51. doi: 10.1093/nar/gkt475. Epub 2013 May 30.

31.

Anything but simple: a phosphorylation-driven toggle within Brd4 triggers gene-specific transcriptional activation.

Laptenko O, Prives C.

Mol Cell. 2013 Mar 7;49(5):838-9. doi: 10.1016/j.molcel.2013.02.021.

32.

MOZ increases p53 acetylation and premature senescence through its complex formation with PML.

Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3895-900. doi: 10.1073/pnas.1300490110. Epub 2013 Feb 19.

33.

Mutant p53 succumbs to starvation.

Moon SH, Prives C.

Cell Cycle. 2013 Mar 15;12(6):867. doi: 10.4161/cc.23911. Epub 2013 Feb 19. No abstract available.

34.

Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress.

Bursać S, Brdovčak MC, Pfannkuchen M, Orsolić I, Golomb L, Zhu Y, Katz C, Daftuar L, Grabušić K, Vukelić I, Filić V, Oren M, Prives C, Volarevic S.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20467-72. doi: 10.1073/pnas.1218535109. Epub 2012 Nov 20.

35.

Mdm2 and MdmX as Regulators of Gene Expression.

Biderman L, Manley JL, Prives C.

Genes Cancer. 2012 Mar;3(3-4):264-73. doi: 10.1177/1947601912455331.

36.

Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes.

Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, Schirmacher P, Prives C.

Mol Cell. 2012 Dec 14;48(5):799-810. doi: 10.1016/j.molcel.2012.09.020. Epub 2012 Oct 24.

37.

The p53-HAT connection: PCAF rules?

Laptenko O, Prives C.

Cell Cycle. 2012 Aug 15;11(16):2975-6. doi: 10.4161/cc.21528. Epub 2012 Aug 14. No abstract available.

38.

Mutant p53: one name, many proteins.

Freed-Pastor WA, Prives C.

Genes Dev. 2012 Jun 15;26(12):1268-86. doi: 10.1101/gad.190678.112. Review.

39.

Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.

Herman AG, Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C, Stockwell BR.

Cancer Discov. 2011 Sep;1(4):312-25. doi: 10.1158/2159-8290.CD-11-0104. Epub 2011 Jul 28.

40.

MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.

Biderman L, Poyurovsky MV, Assia Y, Manley JL, Prives C.

Mol Cell Biol. 2012 Apr;32(7):1214-25. doi: 10.1128/MCB.06150-11. Epub 2012 Jan 30.

41.

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Børresen-Dale AL, Levine AJ, Bargonetti J, Prives C.

Cell. 2012 Jan 20;148(1-2):244-58. doi: 10.1016/j.cell.2011.12.017.

42.

Dissimilar DNA binding by p53 in normal and tumor-derived cells.

Freed-Pastor WA, Prives C.

Cell Cycle. 2011 Dec 15;10(24):4207. doi: 10.4161/cc.10.24.18723. Epub 2011 Dec 15. No abstract available.

PMID:
22127203
43.

p53-Dependent induction of PVT1 and miR-1204.

Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C.

J Biol Chem. 2012 Jan 20;287(4):2509-19. doi: 10.1074/jbc.M111.322875. Epub 2011 Nov 22.

44.

Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11.

Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K, Itoh B, Wang J, Komatsu Y, Yang YR, Hikasa H, Horie Y, Yamashita T, Kamijo T, Zhang Y, Zhu Y, Prives C, Nakano T, Mak TW, Sasaki T, Maehama T, Mori M, Suzuki A.

Nat Med. 2011 Jul 31;17(8):944-51. doi: 10.1038/nm.2392.

45.

DECOD: fast and accurate discriminative DNA motif finding.

Huggins P, Zhong S, Shiff I, Beckerman R, Laptenko O, Prives C, Schulz MH, Simon I, Bar-Joseph Z.

Bioinformatics. 2011 Sep 1;27(17):2361-7. doi: 10.1093/bioinformatics/btr412. Epub 2011 Jul 12.

46.

p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation.

Laptenko O, Beckerman R, Freulich E, Prives C.

Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10385-90. doi: 10.1073/pnas.1105680108. Epub 2011 May 23.

47.

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.

Karni-Schmidt O, Castillo-Martin M, Shen TH, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, Li Y, Lowe S, Prives C, Cordon-Cardo C.

Am J Pathol. 2011 Mar;178(3):1350-60. doi: 10.1016/j.ajpath.2010.11.061. Erratum in: Am J Pathol. 2011 Nov;179(5):2674. HuaiShen, Tian [corrected to Shen, Tian Huai].

48.

Ribosomal protein L37 and the p53 network.

Daftuar L, Zhu Y, Prives C.

Cell Cycle. 2010 Nov 1;9(21):4259. doi: 10.4161/cc.9.21.13527. Epub 2010 Nov 1. No abstract available.

PMID:
21057197
49.

APC/C(Cdc20) targets E2F1 for degradation in prometaphase.

Peart MJ, Poyurovsky MV, Kass EM, Urist M, Verschuren EW, Summers MK, Jackson PK, Prives C.

Cell Cycle. 2010 Oct 1;9(19):3956-64. Epub 2010 Oct 26.

50.

Noncoding RNAs: the missing "linc" in p53-mediated repression.

Barsotti AM, Prives C.

Cell. 2010 Aug 6;142(3):358-60. doi: 10.1016/j.cell.2010.07.029.

Supplemental Content

Loading ...
Support Center